Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization

Roberto M. Lemoli, Antonio De Vivo, Daniela Damiani, Alessandro Isidori, Monica Tani, Alessandro Bonini, Claudia Cellini, Antonio Curti, Luigi Gugliotta, Giuseppe Visani, Renato Fanin, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

We assessed the hematopoietic recovery and transplantation-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (BM). Studied were 86 heavily pretreated consecutive patients with acute leukemia (n = 21), refractory/relapsed non-Hodgkin lymphoma (n = 41) and Hodgkin disease (n = 17), and multiple myeloma (n = 7). There were 78 patients who showed insufficient mobilization of CD34+ cells (<10 cells/μL), whereas 8 patients collected less than 1 × 106 CD34+ cells/kg. BM was primed in vivo for 3 days with 15 to 16 μg/kg of subcutaneous G-CSF. Median numbers of nucleated cells, colony-forming unit cells (CFU-Cs), and CD34+ cells per kilogram harvested were 3.5 × 108, 3.72 × 104, and 0.82 × 106, respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count higher than 0.5 × 109/L and an unsupported platelet count higher than 20 and 50 × 109/L were 13 (range, 8-24), 15 (range, 12-75), and 22 (range, 12-180) days, respectively, for lymphoma/myeloma patients and 23 (range, 13-53), 52 (range, 40-120), and 90 (range, 46-207) days, respectively, for leukemia patients. Median times to hospital discharge after transplantation were 17 (range, 12-40) and 27 (range, 14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6%, whereas 15 patients died of disease. G-CSF-primed BM induces effective multi-lineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization.

Original languageEnglish
Pages (from-to)1595-1600
Number of pages6
JournalBlood
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

Hematopoietic Stem Cell Mobilization
Chemotherapy
Autologous Transplantation
Granulocyte Colony-Stimulating Factor
Hematologic Neoplasms
Stem cells
Bone
Blood
Bone Marrow
Drug Therapy
Recovery
Platelets
Refractory materials
Leukemia
Transplantation
Lymphoma
Peripheral Blood Stem Cells
Mortality
Multiple Myeloma
Hodgkin Disease

ASJC Scopus subject areas

  • Hematology

Cite this

Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. / Lemoli, Roberto M.; De Vivo, Antonio; Damiani, Daniela; Isidori, Alessandro; Tani, Monica; Bonini, Alessandro; Cellini, Claudia; Curti, Antonio; Gugliotta, Luigi; Visani, Giuseppe; Fanin, Renato; Baccarani, Michele.

In: Blood, Vol. 102, No. 5, 01.09.2003, p. 1595-1600.

Research output: Contribution to journalArticle

Lemoli, Roberto M. ; De Vivo, Antonio ; Damiani, Daniela ; Isidori, Alessandro ; Tani, Monica ; Bonini, Alessandro ; Cellini, Claudia ; Curti, Antonio ; Gugliotta, Luigi ; Visani, Giuseppe ; Fanin, Renato ; Baccarani, Michele. / Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. In: Blood. 2003 ; Vol. 102, No. 5. pp. 1595-1600.
@article{ba8538e021424ab2bd166700332be787,
title = "Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization",
abstract = "We assessed the hematopoietic recovery and transplantation-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (BM). Studied were 86 heavily pretreated consecutive patients with acute leukemia (n = 21), refractory/relapsed non-Hodgkin lymphoma (n = 41) and Hodgkin disease (n = 17), and multiple myeloma (n = 7). There were 78 patients who showed insufficient mobilization of CD34+ cells (<10 cells/μL), whereas 8 patients collected less than 1 × 106 CD34+ cells/kg. BM was primed in vivo for 3 days with 15 to 16 μg/kg of subcutaneous G-CSF. Median numbers of nucleated cells, colony-forming unit cells (CFU-Cs), and CD34+ cells per kilogram harvested were 3.5 × 108, 3.72 × 104, and 0.82 × 106, respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count higher than 0.5 × 109/L and an unsupported platelet count higher than 20 and 50 × 109/L were 13 (range, 8-24), 15 (range, 12-75), and 22 (range, 12-180) days, respectively, for lymphoma/myeloma patients and 23 (range, 13-53), 52 (range, 40-120), and 90 (range, 46-207) days, respectively, for leukemia patients. Median times to hospital discharge after transplantation were 17 (range, 12-40) and 27 (range, 14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6{\%}, whereas 15 patients died of disease. G-CSF-primed BM induces effective multi-lineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization.",
author = "Lemoli, {Roberto M.} and {De Vivo}, Antonio and Daniela Damiani and Alessandro Isidori and Monica Tani and Alessandro Bonini and Claudia Cellini and Antonio Curti and Luigi Gugliotta and Giuseppe Visani and Renato Fanin and Michele Baccarani",
year = "2003",
month = "9",
day = "1",
doi = "10.1182/blood-2003-02-0440",
language = "English",
volume = "102",
pages = "1595--1600",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization

AU - Lemoli, Roberto M.

AU - De Vivo, Antonio

AU - Damiani, Daniela

AU - Isidori, Alessandro

AU - Tani, Monica

AU - Bonini, Alessandro

AU - Cellini, Claudia

AU - Curti, Antonio

AU - Gugliotta, Luigi

AU - Visani, Giuseppe

AU - Fanin, Renato

AU - Baccarani, Michele

PY - 2003/9/1

Y1 - 2003/9/1

N2 - We assessed the hematopoietic recovery and transplantation-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (BM). Studied were 86 heavily pretreated consecutive patients with acute leukemia (n = 21), refractory/relapsed non-Hodgkin lymphoma (n = 41) and Hodgkin disease (n = 17), and multiple myeloma (n = 7). There were 78 patients who showed insufficient mobilization of CD34+ cells (<10 cells/μL), whereas 8 patients collected less than 1 × 106 CD34+ cells/kg. BM was primed in vivo for 3 days with 15 to 16 μg/kg of subcutaneous G-CSF. Median numbers of nucleated cells, colony-forming unit cells (CFU-Cs), and CD34+ cells per kilogram harvested were 3.5 × 108, 3.72 × 104, and 0.82 × 106, respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count higher than 0.5 × 109/L and an unsupported platelet count higher than 20 and 50 × 109/L were 13 (range, 8-24), 15 (range, 12-75), and 22 (range, 12-180) days, respectively, for lymphoma/myeloma patients and 23 (range, 13-53), 52 (range, 40-120), and 90 (range, 46-207) days, respectively, for leukemia patients. Median times to hospital discharge after transplantation were 17 (range, 12-40) and 27 (range, 14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6%, whereas 15 patients died of disease. G-CSF-primed BM induces effective multi-lineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization.

AB - We assessed the hematopoietic recovery and transplantation-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (BM). Studied were 86 heavily pretreated consecutive patients with acute leukemia (n = 21), refractory/relapsed non-Hodgkin lymphoma (n = 41) and Hodgkin disease (n = 17), and multiple myeloma (n = 7). There were 78 patients who showed insufficient mobilization of CD34+ cells (<10 cells/μL), whereas 8 patients collected less than 1 × 106 CD34+ cells/kg. BM was primed in vivo for 3 days with 15 to 16 μg/kg of subcutaneous G-CSF. Median numbers of nucleated cells, colony-forming unit cells (CFU-Cs), and CD34+ cells per kilogram harvested were 3.5 × 108, 3.72 × 104, and 0.82 × 106, respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count higher than 0.5 × 109/L and an unsupported platelet count higher than 20 and 50 × 109/L were 13 (range, 8-24), 15 (range, 12-75), and 22 (range, 12-180) days, respectively, for lymphoma/myeloma patients and 23 (range, 13-53), 52 (range, 40-120), and 90 (range, 46-207) days, respectively, for leukemia patients. Median times to hospital discharge after transplantation were 17 (range, 12-40) and 27 (range, 14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6%, whereas 15 patients died of disease. G-CSF-primed BM induces effective multi-lineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization.

UR - http://www.scopus.com/inward/record.url?scp=0041440108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041440108&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-02-0440

DO - 10.1182/blood-2003-02-0440

M3 - Article

C2 - 12714501

AN - SCOPUS:0041440108

VL - 102

SP - 1595

EP - 1600

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -